Search clinical trials for: MK-0941

Total 1790 results

Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Pharmacokinetics & Food Effect of MK-0941 in Adults With Type 2 Diabetes (MK-0941-009)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study of Absorption, Metabolism, Excretion and Mass Balance After a Single Dose Administration of MK-0941 (MK-0941-016)(COMPLETED)

Type 2 Diabetes
Merck Sharp & Dohme LLC

Completed

MK-0941 Multiple Dose Study in Japanese Patients With Type 2 Diabetes (MK-0941-011).

Diabetes Mellitus, Non-Insulin-Dependent
Merck Sharp & Dohme LLC

Completed

A Pharmacokinetic Study of MK-0941 After Multiple Daily Doses in Subjects With Type 2 Diabetes (MK-0941-012)(COMPLETED)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Terminated

A Single Dose Study to Investigate the Pharmacokinetics of MK-0941 in Participants With Renal Insufficiency (MK-0941-015-02)

Type 2 Diabetes
Merck Sharp & Dohme LLC

Completed

Single Doses of MK-0941 in Type 2 Diabetics (MK-0941-027)

Type 2 Diabetes
Lupin Research Inc

Completed

Evaluate the Safety of a Single Oral Dose of Solosec™ (Secnidazole) 2g for the Treatment of Adolescent Girls With BV

Bacterial Vaginoses

United States
Merck Sharp & Dohme LLC

Completed

A Study to Test MK-0941 in Adults With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0941-018)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

An Investigational Drug Study in Adults With Type 2 Diabetes on Basal Insulin (MK-0941-006)

Type 2 Diabetes Mellitus
Genentech, Inc.

Completed

A Study of GDC-0941 in Participants With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable

Solid Cancers

United States
Genentech, Inc.

Completed

A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable

Non-Hodgkin's Lymphoma, Solid Cancers

United Kingdom
Genentech, Inc.

Completed

A Study of the Effect of Formulation and Tablet Hardness on the Bioavailability of Pictilisib in Healthy Volunteers

Healthy Volunteer

United States
Genentech, Inc.

Completed

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0941 Following Single Oral Dose Administration in Healthy Male Subjects

Healthy Volunteer

United States
Merck Sharp & Dohme LLC

Completed

A Study to Test MK-0941 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-0941-017)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Terminated

Dose Range Finding Study of MK-0941 in Patients With Type 2 Diabetes Mellitus on Insulin (MK-0941-007 AM3 EXT1 AM1)(TERMINATED)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Completed

A Study of Caspofungin (MK-0991) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections (MK-0991-074)

Candidiasis, Invasive | Aspergillosis | Candidiasis, Esophageal
Pharmaceutical Project Solutions, Inc.
Cognitive Research Corporation

Completed

PK Study of Intranasal RX0041-002 in Subjects With Severe Renal Impairment and Normal Renal Function

Healthy

United States
Neurocrine Biosciences
Takeda

Completed

Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study

Schizophrenia | Healthy Volunteers

United States
Boehringer Ingelheim

Completed

Safety, Tolerance, and Pharmacokinetics of Single Rising Oral Doses of BILB 1941 ZW Solution in Healthy Male Subjects, Followed With Bioavailability Comparison of BILB 1941 ZW Tablet and Solution Formulation Administered With or Without Food

Healthy
Taisho Pharmaceutical Co., Ltd.

Completed

A Study to Evaluate the Safety and Efficacy of TS-091 in Patients With Narcolepsy

Narcolepsy

Japan, Korea, Republic of
Genentech, Inc.

Terminated

Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors

Solid Tumors

United States
Merck Sharp & Dohme LLC

Completed

A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)

Neoplasms | Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Pancreatic Neoplasms

United States, Australia, Hong Kong, Korea, Republic of, New Zealand, Singapore, Taiwan
Medical Research Council
Merck Sharp & Dohme LLC; Aarhus University Hospital; NCRI Clinical Studies Groups and other collaborators

Unknown

Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475

Glioblastoma

United States, Italy, Belgium, Germany, Poland, Russian Federation, Spain, Switzerland, Ukraine, United Kingdom
Wyeth is now a wholly owned subsidiary of Pfizer

Withdrawn

Study Evaluating Orally Administered ERB-041 in Subjects With Active Interstitial Cystitis

Cystitis, Interstitial

United States, Austria, Germany
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study to Evaluate Multiple Doses of ERB-041 in Healthy, Female Japanese Subjects

Healthy

Japan
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Safety and Efficacy of ERB-041 on Reduction of Symptoms Associated With Endometriosis in Reproductive-Aged Women

Endometriosis | Dysmenorrhea | Pelvic Pain | Dyspareunia

Hong Kong, United States, Canada, Australia, United Kingdom, South Africa, Belgium
Merck Sharp & Dohme LLC
Mycoses Study Group

Terminated

Pilot Feasibility Study With Patients Who Are at High Risk For Developing Invasive Candidiasis in a Critical Care Setting (MK-0991-067)

Invasive Candidiasis
Yongchang Zhang
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.

Completed

First-in-Human Phase I/II Study of FHND-9041 in Patients With EGFR Mutated Advanced Non-Small Cell Lung Cancer (Helpful)

Non-small Cell Lung Cancer | EGFR Gene Mutation | EGFR-TKI Sensitizing Mutation

China
Merck Sharp & Dohme LLC

Terminated

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Neoplasms Malignant
Innate Pharma

Completed

Safety and Tolerability of NNC0141-0000-0100 in Subjects With Rheumatoid Arthritis

Inflammation | Rheumatoid Arthritis

Germany
Merck Sharp & Dohme LLC

Completed

A Single and Multiple-Dose Study of MK-8521 in Healthy and Obese Males (MK-8521-002)

Type 2 Diabetes Mellitus
Genentech, Inc.

Completed

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy

Breast Cancer

Belgium, Israel, United States, Spain, Denmark, Germany, Hong Kong, Russian Federation, Australia, New Zealand, Korea, Republic of, Malaysia, Singapore, Italy, Czech Republic, France, Peru, Canada, United Kingdom, Chile, Thailand, Argentin... and more
First Affiliated Hospital of Fujian Medical University

Recruiting

[68Ga]Ga-P15-041 PET/CT in Variety of Bone Tumors

Bone Metastases | Bone Tumor

China
Shenzhen Salubris Pharmaceuticals Co., Ltd.

Completed

SAL-0951 Tablets in the Treatment of Renal Anemia in Non-dialysis Chronic Kidney Disease

Renal Anemia in Non-dialysis Chronic Kidney Disease

China
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating ERB-041 in Endometriosis in Reproductive-Age Women

Endometriosis

United States
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma

Multiple Myeloma | Advanced Solid Tumors

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating ERB-041 in Active Crohn's Disease

Crohn's Disease
Merck Sharp & Dohme LLC

Completed

A Single Rising Dose Study of MK-8150 (MK-8150-001)

Hypertension | Isolated Systolic Hypertension (ISH)
Taisho Pharmaceutical Co., Ltd.

Completed

Clinical Study on Histamine H3 Receptor Occupancy of TS-091 by PET Examination in Healthy Adult Subjects

Healthy Subjects

Japan
Genentech, Inc.

Completed

A Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0941 and the Effect of Food and Proton Pump Inhibition on GDC-0941 Tablet Pharmacokinetics in Healthy Volunteers

Healthy Volunteers

United States
Five Eleven Pharma, Inc.

Completed

Preliminary Evaluation of Uptake in Bone Metastases and Biodistribution of [68Ga]P15-041

Prostate Cancer | Bone Metastases

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Mixed Adenocarcinoma | Endometrial...

United States
Genentech, Inc.

Completed

A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Participants With Locally Recurrent or Metastatic Breast Cancer

Breast Cancer

United States, Korea, Republic of, Australia, Austria, Czechia, United Kingdom, Belgium, Spain
Merck Sharp & Dohme LLC

Completed

A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)

Schizophrenia

United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effects of Single Doses of MK-1064 and MK-6096 on Polysomnography (PSG) (MK-1064-003)

Polysomnography
Merck Sharp & Dohme LLC

Completed

A Multiple-Dose Study to Evaluate MK-1075 in Hepatitis C Virus (HCV) Infected Participants (MK-1075-004)

Hepatitis C Virus Infection
Merck Sharp & Dohme LLC

Completed

A Single Dose Study of MK-8266 (MK-8266-001)

Hypertension
Merck Sharp & Dohme LLC

Completed

A Study of the Efficacy and Safety of MK-5475 in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)

Pulmonary Arterial Hypertension | Hypertension, Pulmonary

United States, Argentina, Australia, Belgium, Canada, Colombia, France, Germany, Greece, Israel, Italy, Mexico, New Zealand, Poland, Russian Federation, Sweden, Turkey, United Kingdom
Merck Sharp & Dohme LLC

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-005)

Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC

Completed

A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8150 (MK-8150-002)

Hypertension | Isolated Systolic Hypertension

3

Subscribe